MX2016007567A - Un nuevo compuesto de triazolo-piridina. - Google Patents

Un nuevo compuesto de triazolo-piridina.

Info

Publication number
MX2016007567A
MX2016007567A MX2016007567A MX2016007567A MX2016007567A MX 2016007567 A MX2016007567 A MX 2016007567A MX 2016007567 A MX2016007567 A MX 2016007567A MX 2016007567 A MX2016007567 A MX 2016007567A MX 2016007567 A MX2016007567 A MX 2016007567A
Authority
MX
Mexico
Prior art keywords
pyridine compound
group
novel triazolo
triazolo
novel
Prior art date
Application number
MX2016007567A
Other languages
English (en)
Inventor
Hamdouchi Chafiq
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2016007567A publication Critical patent/MX2016007567A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la fórmula (ver Fórmula) en donde R1 se selecciona del grupo que consiste en H y CH3; R2 se selecciona del grupo que consiste en H y CH3; R3 se selecciona del grupo que consiste en H, alquilo C1-C3, O(CH2)3SO2CH3, O(CH2)2OCH3, O(CH2)2C(CH3)2OH, CN y OCF2; o una de sus sales farmacéuticas, métodos de tratamiento de diabetes, intermediarios y un proceso para preparar compuestos de la invención.
MX2016007567A 2013-12-13 2014-12-04 Un nuevo compuesto de triazolo-piridina. MX2016007567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361915774P 2013-12-13 2013-12-13
PCT/US2014/068487 WO2015088868A1 (en) 2013-12-13 2014-12-04 A novel triazolo-pyridine compound

Publications (1)

Publication Number Publication Date
MX2016007567A true MX2016007567A (es) 2017-01-06

Family

ID=52144909

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007567A MX2016007567A (es) 2013-12-13 2014-12-04 Un nuevo compuesto de triazolo-piridina.

Country Status (14)

Country Link
US (1) US9120793B2 (es)
EP (1) EP3080093B1 (es)
JP (1) JP6152227B2 (es)
KR (1) KR20160077207A (es)
CN (1) CN105814026B (es)
AR (1) AR098522A1 (es)
AU (1) AU2014364224B2 (es)
BR (1) BR112016012123A8 (es)
CA (1) CA2929317A1 (es)
EA (1) EA201690879A1 (es)
ES (1) ES2653522T3 (es)
MX (1) MX2016007567A (es)
TW (1) TW201609722A (es)
WO (1) WO2015088868A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105873929B (zh) 2014-01-10 2018-04-06 伊莱利利公司 苯基三唑并吡啶化合物
EP3092240B1 (en) 2014-01-10 2018-12-05 Eli Lilly and Company Isopropyl triazolo pyridine compounds
US10106553B2 (en) 2016-04-11 2018-10-23 Janssen Pharmaceutica Nv Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
WO2017180457A1 (en) 2016-04-11 2017-10-19 Janssen Pharmaceutica Nv Gpr40 agonists in anti-diabetic drug combinations
AU2019222644B2 (en) 2018-02-13 2021-04-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
EP4234030A3 (en) 2018-07-13 2023-10-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1706386A1 (en) * 2003-12-22 2006-10-04 Eli Lilly And Company Bicyclic derivatives as ppar modulators
CN1946666A (zh) * 2004-02-27 2007-04-11 埃姆艮股份有限公司 用于治疗代谢性疾病的化合物、药物组合物和方法
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
EP2061760A1 (en) * 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
ES2423793T3 (es) * 2008-05-26 2013-09-24 Genfit Compuestos agonistas de PPAR, preparación y usos para el tratamiento de la diabetes y/o dislipidemias
US8530413B2 (en) * 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物

Also Published As

Publication number Publication date
CA2929317A1 (en) 2015-06-18
WO2015088868A1 (en) 2015-06-18
CN105814026B (zh) 2018-08-10
TW201609722A (zh) 2016-03-16
EP3080093B1 (en) 2017-10-04
US20150166535A1 (en) 2015-06-18
EA201690879A1 (ru) 2016-10-31
EP3080093A1 (en) 2016-10-19
US9120793B2 (en) 2015-09-01
JP6152227B2 (ja) 2017-06-21
AU2014364224B2 (en) 2017-02-16
KR20160077207A (ko) 2016-07-01
CN105814026A (zh) 2016-07-27
ES2653522T3 (es) 2018-02-07
JP2016539984A (ja) 2016-12-22
AR098522A1 (es) 2016-06-01
AU2014364224A1 (en) 2016-05-19
BR112016012123A8 (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
MX2016007567A (es) Un nuevo compuesto de triazolo-piridina.
CY1120188T1 (el) ΠΑΡΑΓΩΓΑ ΝΑΦΘΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΙΝΤΕΓΚΡΙΝΗΣ αvβ6
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MX2016008910A (es) Compuestos de fenil-triazolo-piridina.
NZ732649A (en) Picolinamides and related compounds
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
PE20160523A1 (es) Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis
NZ726356A (en) Processes for preparing antiviral compounds
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
MY172860A (en) Dimethyl-benzoic acid compounds
MX2018005133A (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
PH12017501652A1 (en) Kv1.3 inhibitors and their medical application
MX2015017156A (es) Inhibidores de bace.
MY169028A (en) Process for making hydroxylated cyclopentylpyrimidine compounds
MX2017003238A (es) Metodo para preparar 2'-o-fucosil-lactosa.
EA201490754A1 (ru) Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора
EA201491276A1 (ru) Новые производные бензилсульфонамида, подходящие для применения в качестве ингибиторов mogat-2
EA201891769A1 (ru) СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ ПИРРОЛО[3,2-d]ПИРИМИДИНА И ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
MX2021011971A (es) Proceso para preparar cicloserinas sustituidas.
MX2016007985A (es) Compuestos de fluorofenilpirazol.
EA201991887A1 (ru) Замещенные эфиры бензил-4-аминопиколиновой кислоты и эфиры пиримидин-4-карбоновой кислоты, способы их получения, а также их применение в качестве гербицидов и регуляторов роста
IN2015DN02514A (es)
AR089838A1 (es) Derivados de sitaxetan